Forbes -- Regenerative medicine company Tengion Inc. plans to raise as much as $44.4 million in an initial public offering this week. Tengion plans to sell 4.4 million shares for $8 to $10 apiece. Current stockholders have asked to buy about $15 million in stock. Meanwhile, the deal's underwriter's can buy up to 666,667 shares of stock to cover excess demand.
